Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug slow cataracts?

NCT ID NCT07176338

Knowledge-focused Sponsor: Vienna Institute for Research in Ocular Surgery Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study looks at whether metformin, a standard diabetes medicine, gets into the lens capsule of the eye and can slow the growth of lens cells that cause cataracts. Researchers will collect blood and lens tissue from 40 people with type 2 diabetes and age-related cataracts who already take metformin. The goal is to measure metformin levels in the lens and see if it reduces lens cell growth in lab tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If successful, this could point toward a way to slow cataract formation in people with diabetes.
What could go wrong
This is a very early, small pilot study (40 people) that only tests cells in a lab, not in the eye. It may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Oct 2022

Expected to finish

Oct 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 105 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age-related cataract * Diabetes mellitus type II * Metformin treatment * Age 21 or older * Written informed consent prior to surgery Exclusion Criteria: * Diabetes mellitus type I * Previous ocular surgery or trauma regarding cataract surgery * Previous vitrectomy * Pregnancy (pregnancy test will be taken in women of reproductive age)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract senile cataract type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Diabetes mellitus type 2

Contacts and locations

Locations

  • Vienna Institute for Research in Ocular Surgery (VIROS)

    Vienna, 1140, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.